A Setback for TNBC Monitoring With Circulating Tumor DNA in ZEST Trial

(MedPage Today) -- SAN ANTONIO -- A first-in-kind trial of molecular residual disease (MRD)-guided therapy in breast cancer came to an early end because of low randomization, but insights can still be gained on the potential use for circulating...